Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2017, Article ID 4020198, 7 pages
https://doi.org/10.1155/2017/4020198
Research Article

Genetic Variations and mRNA Expression of NRF2 in Parkinson’s Disease

1Department of Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden
2Department of Clinical Neuroscience, Karolinska Institutet, 17177 Stockholm, Sweden
3Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 17177 Stockholm, Sweden
4Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 14183 Huddinge, Sweden
5Department of Women’s and Children’s Health, Karolinska Institutet, 17176 Stockholm, Sweden

Correspondence should be addressed to Caroline Ran; es.ik@nar.enilorac

Received 18 November 2016; Revised 6 April 2017; Accepted 12 April 2017; Published 2 May 2017

Academic Editor: Hélio Teive

Copyright © 2017 Caroline Ran et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Ran and A. C. Belin, “The genetics of Parkinson's disease: review of current and emerging candidates,” Journal of Parkinsonism and Restless Legs Syndrome, vol. 2014, no. 4, pp. 63–75, 2014. View at Google Scholar
  2. P. Moi, K. Chan, I. Asunis, A. Cao, and Y. W. Kan, “Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the β-globin locus control region,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 21, pp. 9926–9930, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. T. W. Kensler, N. Wakabayashi, and S. Biswal, “Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 89–116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. P.-H. Shih and G.-C. Yen, “Differential expressions of antioxidant status in aging rats: the role of transcriptional factor Nrf2 and MAPK signaling pathway,” Biogerontology, vol. 8, no. 2, pp. 71–80, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Itoh, T. Chiba, S. Takahashi et al., “An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements,” Biochemical and Biophysical Research Communications, vol. 236, no. 2, pp. 313–322, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Suh, S. V. Shenvi, B. M. Dixon et al., “Decline in transcriptional activity of Nrf2 causes age-related loss of glutathione synthesis, which is reversible with lipoic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 10, pp. 3381–3386, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. C. P. Ramsey, C. A. Glass, M. B. Montgomery et al., “Expression of Nrf2 in neurodegenerative diseases,” Journal of Neuropathology and Experimental Neurology, vol. 66, no. 1, pp. 75–85, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. Y.-C. Chen, Y.-R. Wu, Y.-C. Wu, G.-J. Lee-Chen, and C.-M. Chen, “Genetic analysis of NFE2L2 promoter variation in Taiwanese Parkinson's disease,” Parkinsonism and Related Disorders, vol. 19, no. 2, pp. 247–250, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Gui, L. Zhang, W. Lv, W. Zhang, J. Zhao, and X. Hu, “NFE2L2 variations reduce antioxidant response in patients with Parkinson disease,” Oncotarget, vol. 7, no. 10, pp. 10756–10764, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Todorovic, J. R. B. Newman, J. Shan et al., “Comprehensive assessment of genetic sequence variants in the antioxidant 'master regulator' Nrf2 in idiopathic parkinson's disease,” PLoS ONE, vol. 10, no. 5, Article ID e0128030, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. M. von Otter, S. Landgren, S. Nilsson et al., “Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease,” BMC Medical Genetics, vol. 11, no. 1, article 36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. M. von Otter, P. Bergström, A. Quattrone et al., “Genetic associations of Nrf2-encoding variants with Parkinson's disease — a multicenter study,” BMC Medical Genetics, vol. 15, no. 1, article 131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. M. von Otter, S. Landgren, S. Nilsson et al., “Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer's disease and age-related cataract,” Mechanisms of Ageing and Development, vol. 131, no. 2, pp. 105–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Bergström, M. Von Otter, S. Nilsson et al., “Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis,” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 15, no. 1-2, pp. 130–137, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. S. E. Daniel and A. J. Lees, “Parkinson's Disease Society Brain Bank, London: overview and research,” Journal of Neural Transmission. Supplementa, vol. 39, pp. 165–172, 1993. View at Google Scholar
  16. C. Ran, On Genes Involved in Common Neurological Disorders: Focus on Parkinson's Disease. Karolinska Institutet, Sweden, Stockholm, 2014.
  17. M. Ronaghi, M. Uhlén, and P. Nyrén, “A sequencing method based on real-time pyrophosphate,” Science, vol. 281, no. 5375, pp. 363–365, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. E. V. Walls, M. G. Doyle, K. K. Patel, M. J. Allday, D. Catovsky, and D. H. Crawford, “Activation and immortalization of leukaemic B cells by Epstein-Barr virus,” International Journal of Cancer, vol. 44, no. 5, pp. 846–853, 1989. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Purcell, B. Neale, K. Todd-Brown et al., “PLINK: a tool set for whole-genome association and population-based linkage analyses,” American Journal of Human Genetics, vol. 81, no. 3, pp. 559–575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Rodriguez, T. R. Gaunt, and I. N. M. Day, “Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies,” American Journal of Epidemiology, vol. 169, no. 4, pp. 505–514, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. J. C. Barrett, B. Fry, J. Maller, and M. J. Daly, “Haploview: analysis and visualization of LD and haplotype maps,” Bioinformatics, vol. 21, no. 2, pp. 263–265, 2005. View at Publisher · View at Google Scholar
  22. J. Hellemans, G. Mortier, A. de Paepe, F. Speleman, and J. Vandesompele, “qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data,” Genome Biology, vol. 8, no. 2, p. R19, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Marzec, J. D. Christie, S. P. Reddy et al., “Functional polymorphisms in the transcription factor NRF2 in humans increase the risk of acute lung injury,” FASEB Journal, vol. 21, no. 9, pp. 2237–2246, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C.-C. Hua, L.-C. Chang, J.-C. Tseng, C.-M. Chu, Y.-C. Liu, and W.-B. Shieh, “Functional haplotypes in the promoter region of transcription factor Nrf2 in chronic obstructive pulmonary disease,” Disease Markers, vol. 28, no. 3, pp. 185–193, 2010. View at Publisher · View at Google Scholar · View at Scopus